This medication is now FDA-approved for weight management and works by mimicking a hormone called GLP-1, which regulates appetite and food intake
Final Verdict: 7 Clinical Facts Ozempic is not licensed for weight loss in the UK Wegovy is the licensed semaglutide weight management product Mounjaro and Wegovy are different drugs tirzepatide (dual GLP-1/GIP) vs semaglutide (GLP-1 only) In the SURMOUNT-5 head-to-head trial, Mounjaro produced 20.2% vs Wegovys 13.7% average weight loss Wegovy is approximately 75/month cheaper at Slinic maintenance doses important for cost-sensitive patients Wegovy has the NICE cardiovascular indication (April 2026) Mounjaro does not yet have this label Wegovy now has a licensed oral version (MHRA June 2026) Mounjaro does not yet have an oral equivalent Neither Ozempic off-label nor compounded alternatives are appropriate when licensed products are readily available from a GPhC-registered UK pharmacy Slinic prescribes Mounjaro and Wegovy both correctly licensed, both from Eli Lilly and Novo Nordisk authorised supply chains, both reviewed by a registered UK prescriber
Because NAION can occur in people with diabetes, hypertension, sleep apnea, and other vascular conditions, each case typically requires an individualized review of the patients medical history and risk factors
In addition, it would be instructive to compare behavioral WL with behavioral WL coupled with a GLP-1 agonist
In the brain, this was reflected in increased FC between the homeostatic and motivational hubs as well as increases in phasic reward-related signals in the NAcc (during the task-free phase) and the VTA/substantia nigra (during the task)
Abnormalities of vitamin D and calcium metabolism after surgical treatment of morbid obesity: a study of 136 patients
